Advances in management of pediatric chronic immune thrombocytopenia: a narrative review

키워드

참고문헌 (62)

1. Lim JH, "Epidemiology and viral etiology of pediatric immune thrombocytopenia through Korean public health data analysis", J Clin Med, 10, pp.1356~ (2021)
2. Cooper N, "Immune thrombocytopenia", N Engl J Med, 381, pp.945~955 (2019)
3. Bennett CM, "Predictors of remission in children with newly diagnosed immune thrombocytopenia : data from the Intercontinental Cooperative ITP Study Group Registry II participants", Pediatr Blood Cancer, 65, pp.e26736~ (2018)
4. Grainger JD, "Changing trends in the UK management of childhood ITP", Arch Dis Child, 97, pp.8~11 (2012)
5. Grimaldi-Bensouda L, "Childhood immune thrombocytopenia : a nationwide cohort study on condition management and outcomes", Pediatr Blood Cancer, 64, pp.e26389~ (2017)
6. Kühne T, "Newly diagnosed idiopathic thrombocytopenic purpura in childhood : an observational study", Lancet, 358, pp.2122~2125 (2001)
7. Lilleyman JS, "Intracranial haemorrhage in idiopathic thrombocytopenic purpura : Paediatric Haematology Forum of the British Society for Haematology", Arch Dis Child, 71, pp.251~253 (1994)
8. Iyori H, "Intracranial hemorrhage in children with immune thrombocytopenic purpura", Ann Hematol, 79, pp.691~695 (2000)
9. Neunert CE, "Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura", Blood, 112, pp.4003~4008 (2008)
10. Neunert CE, "Bleeding manifestations and management of children with persistent and chronic immune thrombocytopenia : data from the Intercontinental Cooperative ITP Study Group(ICIS)", Blood, 121, pp.4457~4462 (2013)
11. Choudhary DR, "Intracranial hemorrhage in childhood immune thrombocytopenic purpura", Pediatr Blood Cancer, 52, pp.529~531 (2009)
12. Psaila B, "Intracranial hemorrhage(ICH)in children with immune thrombocytopenia(ITP) : study of 40 cases", Blood, 114, pp.4777~4783 (2009)
13. Elalfy M, "Intracranial hemorrhage in acute and chronic childhood immune thrombocytopenic purpura over a ten-year period : an Egyptian multicenter study", Acta Haematol, 123, pp.59~63 (2010)
14. Jaime-Pérez JC, "Insights on chronic immune thrombocytopenia pathogenesis : a bench to bedside update", Blood Rev, 49, pp.100827~ (2021)
15. Rodeghiero F, "Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children : report from an international working group", Blood, 113, pp.2386~2393 (2009)
16. Kühne T, "Newly diagnosed immune thrombocytopenia in children and adults : a comparative prospective observational registry of the Intercontinental Cooperative Immune Thrombocytopenia Study Group", Haematologica, 96, pp.1831~1837 (2011)
17. Schifferli A, "A comparative prospective observational study of children and adults with immune thrombocytopenia : 2-year follow-up", Am J Hematol, 93, pp.751~759 (2018)
18. Jae Yeob Jung, "http:", 10.3345, pp.kjp.2016.59.8.335 335 Korean J Pediatr 2016;59(8):335-340 Clinical course and prognostic factors of childhood immune thrombocytopenia: single center experience of 10 years, Clinical and Experimental Pediatrics[DOI]
19. 윤회수, "High Remission Rate of Chronic Immune Thrombocytopenia in Children: Result of 20-Year Follow-Up", Yonsei Medical Journal, 57(1), pp.127~131 (2016), 연세대학교의과대학[DOI]
20. 심예지, "Natural course of childhood chronic immune thrombocytopenia using the revised terminology and definitions of the international working group: a single center experience", Blood Research, 49(3), pp.187~191 (2014), 대한혈액학회
21. 김지윤, "Diagnostic Approach of Childhood Immune Thrombocytopenia", Clinical Pediatric Hematology-Oncology, 25(1), pp.10~16 (2018), 대한소아혈액종양학회[DOI]
22. Neunert C, "The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia", Blood, 117, pp.4190~4207 (2011)
23. Provan D, "Updated international consensus report on the investigation and management of primary immune thrombocytopenia", Blood Adv, 3, pp.3780~3817 (2019)
24. Nomura S, "Advances in diagnosis and treatments for immune thrombocytopenia", Clin Med Insights Blood Disord, 9, pp.15~22 (2016)
25. Mitchell WB, "Effect of thrombopoietin receptor agonists on the apoptotic profile of platelets in patients with chronic immune thrombocytopenia", Am J Hematol, 89, pp.E228~34 (2014)
26. Neunert C, "American Society of Hematology 2019 guidelines for immune thrombocytopenia", Blood Adv, 3, pp.3829~3866 (2019)
27. Wire MB, "A randomized, open-label, 5-period, balanced crossover study to evaluate the relative bioavailability of eltrombopag powder for oral suspension(PfOS)and tablet formulations and the effect of a high-calcium meal on eltrombopag pharmacokinetics when administered with or 2 hours before or after PfOS", Clin Ther, 34, pp.699~709 (2012)
28. Deng Y, "Metabolism and disposition of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist, in healthy human subjects", Drug Metab Dispos, 39, pp.1734~1746 (2011)
29. Grainger JD, "Eltrombopag for children with chronic immune thrombocytopenia(PETIT2) : a randomised, multicentre, placebo-controlled trial", Lancet, 386, pp.1649~1658 (2015)
30. Bussel JB, "Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia(PETIT) : a randomised, multicentre, placebo-controlled study", Lancet Haematol, 2, pp.e315~25 (2015)
31. Giordano P, "Use of eltrombopag in children with chronic immune thrombocytopenia(ITP) : a real life retrospective multicenter experience of the Italian Association of Pediatric Hematology and Oncology(AIEOP)", Front Med(Lausanne), 7, pp.66~ (2020)
32. Bussel JB, "A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia", Blood, 118, pp.28~36 (2011)
33. Bussel JB, "Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia(ITP)", Pediatr Blood Cancer, 62, pp.208~213 (2015)
34. Tarantino MD, "Romiplostim in children with immune thrombocytopenia : a phase 3, randomised, double-blind, placebo-controlled study", Lancet, 388, pp.45~54 (2016)
35. Neunert CE, "Romiplostim for the management of pediatric immune thrombocytopenia : drug development and current practice", Blood Adv, 3, pp.1907~1915 (2019)
36. Newland A, "Remission and platelet responses with romiplostim in primary immune thrombocytopenia : final results from a phase 2 study", Br J Haematol, 172, pp.262~273 (2016)
37. Kuter DJ, "Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia(ITP)for up to 1 year and in those with chronic ITP for more than 1 year : a subgroup analysis of integrated data from completed romiplostim studies", Br J Haematol, 185, pp.503~513 (2019)
38. Reff ME, "Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20", Blood, 83, pp.435~445 (1994)
39. Bennett CM, "Prospective phase 1", 2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura, 2006, pp.107, 2639~2642
40. Parodi E, "Long-term follow-up analysis after rituximab therapy in children with refractory symptomatic ITP : identification of factors predictive of a sustained response", Br J Haematol, 144, pp.552~558 (2009)
41. Tamminga RY, "Rituximab treatment for symptomatic chronic ITP", Pediatr Blood Cancer, 47(5 Suppl), pp.714~716 (2006)
42. Wang J, "Chronic immune thrombocytopenic purpura in children : assessment of rituximab treatment", J Pediatr, 146, pp.217~221 (2005)
43. Kochhar M, "Immune thrombocytopenia : a review of upfront treatment strategies", Blood Rev, 49, pp.100822~ (2021)
44. Patel VL, "Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia", Blood, 119, pp.5989~5995 (2012)
45. Zaja F, "Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia", Blood, 115, pp.2755~2762 (2010)
46. Gudbrandsdottir S, "Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia", Blood, 121, pp.1976~1981 (2013)
47. Wang J, "Efficacy and safety of the combination treatment of rituximab and dexamethasone for adults with primary immune thrombocytopenia(ITP) : a meta-analysis", Biomed Res Int, 2018, pp.1316096~ (2018)
48. Oved JH, "Treatment of children with persistent and chronic idiopathic thrombocytopenic purpura : 4 infusions of rituximab and three 4-day cycles of dexamethasone", J Pediatr, 191, pp.225~231 (2017)
49. Moss C, "Thrombocytopenia in systemic lupus erythematosus responsive to dapsone", BMJ, 297, pp.266~ (1988)
50. Rodrigo C, "Dapsone for primary immune thrombocytopenia in adults and children : an evidence-based review", J Thromb Haemost, 11, pp.1946~1953 (2013)
51. Godeau B, "Dapsone for chronic autoimmune thrombocytopenic purpura : a report of 66 cases", Br J Haematol, 97, pp.336~339 (1997)
52. Khera S, "Dapsone : an old but effective therapy in pediatric refractory immune thrombocytopenia", Indian J Hematol Blood Transfus, 36, pp.690~694 (2020)
53. Avila ML, "Long-term outcomes after splenectomy in children with immune thrombocytopenia : an update on the registry data from the Intercontinental Cooperative ITP Study Group", Haematologica, 105, pp.2682~2685 (2020)
54. Boyle S, "Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia", Blood, 121, pp.4782~4790 (2013)
55. El-Alfy MS, "5-to 16-year follow-up following splenectomy in chronic immune thrombocytopenic purpura in children", Acta Haematol, 110, pp.20~24 (2003)
56. Radaelli F, "Factors predicting response to splenectomy in adult patients with idiopathic thrombocytopenic purpura", Haematologica, 85, pp.1040~1044 (2000)
57. Hemmila MR, "The response to splenectomy in pediatric patients with idiopathic thrombocytopenic purpura who fail high-dose intravenous immune globulin", J Pediatr Surg, 35, pp.967~972 (2000)
58. Law C, "High-dose intravenous immune globulin and the response to splenectomy in patients with idiopathic thrombocytopenic purpura", N Engl J Med, 336, pp.1494~1498 (1997)
59. Holt D, "Response to intravenous immunoglobulin predicts splenectomy response in children with immune thrombocytopenic purpura", Pediatrics, 111, pp.87~90 (2003)
60. Grainger JD, "Health-related quality of life in children with chronic immune thrombocytopenia treated with eltrombopag in the PETIT study", Br J Haematol, 185, pp.102~106 (2019)
61. Mathias SD, "A phase 3, randomized, double-blind, placebo-controlled study to determine the effect of romiplostim on health-related quality of life in children with primary immune thrombocytopenia and associated burden in their parents", Pediatr Blood Cancer, 63, pp.1232~1237 (2016)
62. Klaassen RJ, "Pilot study of the effect of romiplostim on child health-related quality of life(HRQoL)and parental burden in immune thrombocytopenia(ITP)", Pediatr Blood Cancer, 58, pp.395~398 (2012)

관련 논문AI추천